AR065854A1 - Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros. - Google Patents

Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros.

Info

Publication number
AR065854A1
AR065854A1 ARP080101248A ARP080101248A AR065854A1 AR 065854 A1 AR065854 A1 AR 065854A1 AR P080101248 A ARP080101248 A AR P080101248A AR P080101248 A ARP080101248 A AR P080101248A AR 065854 A1 AR065854 A1 AR 065854A1
Authority
AR
Argentina
Prior art keywords
dimethyl
compound
formula
alkoxy
alkyl
Prior art date
Application number
ARP080101248A
Other languages
English (en)
Inventor
Chris Richard Melville
David Mark Rotstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065854(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR065854A1 publication Critical patent/AR065854A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de la formula I, en la que R es (a) cicloalquilo C3-6 dicho cicloalquilo está opcionalmente sustituido de una a tres veces por restos elegidos con independencia entre el grupo formado por hidroxi, alquilo C1-3, oxo, halogeno, alcoxi C1-6-oximino y alcoxi C1-6-alcoxi C1-6; (b) (cicloalquilo C3-6)-alquilo C1-3, dicho cicloalquilo está opcionalmente sustituido de una a tres veces por restos elegidos con independencia entre el grupo formado por hidroxi, alquilo C1-3, oxo, halogeno,alcoxi C1-6-oximino y alcoxi C1-6-alcoxi C1-6, con la condicion de que dicho (cicloalquilo C3-6)-alquilo C1-3 no sea 4,4-difluorociclohexil-metilo ni 1-hidroxil-ciclohexil-metilo, (c) el compuesto de la formula (2) en el que R6 es hidrogeno ohalogeno; (d) el compuesto de la formula (3); (e) el compuesto de la formula (4), (f) el compuesto de la formula (5) en el que m es 0 o 2; (g) heteroarilo, heteroaril-alquilo C1-3, fenilalquilo C1-3 en el que dicho heteroarilo es piridina,pirimidina, pirazina o piridazina y dicho heteroarilo o dicho fenilo está sustituido con independencia por 1-3 sustituyentes elegidos con independencia entre alquilo C1-3, halogeno, alcoxi C1-6, ciano y nitro (h) haloalquilo C1-3 (i) el compuesto dela formula (6), (j) el compuesto de la formula (7), (k) el compuesto de la formula (8), (m) el compuesto de la formula (9); R2 es alquilo C1-6; R3 es hidrogeno o alquilo C1-3; R4 es elegido entre el grupo formado por (a) - (i) y (j): (a) 4,6-dimetil-pirimidin-5-ilo; (b) 4,6-dimetil-2-trifluormetil-pirimidin-5-ilo; (c) 2,4-dimetil-piridin-3-ilo; (d) 2,4-dimetil-1-oxi-piridin-3-il Ç 6-ciano-2,4-dimetil-piridin-3-ilo; (f) 2,4-dimetil-6-oxo-6H-piran-3-il (g) 2,4-dimetil-6-oxo-1,6-dihidro-piridin-3-ilo; (h) 1,2,4-trimetil-6-oxo-1,6-dihidro-piridin-3-ilo; (i) 3,5-dimetil-1-oxi-1H-pirazol-4-ilo; y (j) 5-ciano-2,4-dimetil-1H-pirrol-3-ilo; o (k) 3-metil-5-trifluormetil-isoxasol-4-il (l) 3,5-dimetil-1-hidroxi-pirazol-4-ilo; R6 es acilo C1-6,(alcoxi C1-6)-carbonilo, (alquilo C1-6)-SO, haloalquilo C1-6, cicloalquilo C3-6, oxetanilo, tetrahidrofuranilo o tetrahidropiranilo y n es 0-3; p es el numero 1 o 3; o una sal de adicion de ácido farmacéuticamente aceptable del mismo.
ARP080101248A 2007-03-29 2008-03-27 Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros. AR065854A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92069407P 2007-03-29 2007-03-29

Publications (1)

Publication Number Publication Date
AR065854A1 true AR065854A1 (es) 2009-07-08

Family

ID=39535486

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101248A AR065854A1 (es) 2007-03-29 2008-03-27 Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros.

Country Status (15)

Country Link
US (1) US7625891B2 (es)
EP (1) EP2142555A1 (es)
JP (1) JP2010522707A (es)
KR (1) KR20090127298A (es)
CN (1) CN101646679A (es)
AR (1) AR065854A1 (es)
AU (1) AU2008233930A1 (es)
BR (1) BRPI0809646A2 (es)
CA (1) CA2682639A1 (es)
CL (1) CL2008000863A1 (es)
IL (1) IL200661A0 (es)
MX (1) MX2009010503A (es)
PE (1) PE20090183A1 (es)
TW (1) TW200902020A (es)
WO (1) WO2008119663A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5451611B2 (ja) * 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
WO2009037168A1 (en) * 2007-09-19 2009-03-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
US8598160B2 (en) * 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CL2009001058A1 (es) 2008-05-01 2010-09-10 Vitae Pharmaceuticals Inc Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
PL2300461T3 (pl) * 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2687525B1 (en) 2008-07-25 2015-09-23 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
KR20110063438A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
KR20200003933A (ko) 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
WO2018048261A1 (ko) * 2016-09-08 2018-03-15 가천대학교 산학협력단 신규 스피로퀴논 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 신경계 질환의 예방 또는 치료용 약학적 조성물
CN109012748B (zh) * 2018-07-27 2021-03-16 安徽师范大学 吡啶取代吡咯基稀土金属催化剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127065C (es) * 1964-04-22
HU204529B (en) 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
US6291469B1 (en) 1995-09-29 2001-09-18 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
ATE299866T1 (de) 1999-05-04 2005-08-15 Schering Corp Piperidinderivate verwendbar als ccr5 antagonisten
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
CZ20013940A3 (cs) 1999-05-04 2002-04-17 Schering Corporation Piperazinové deriváty uľitečné jako CCR5 antagonisté
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
ATE283854T1 (de) 1999-12-03 2004-12-15 Ono Pharmaceutical Co Triazaspiro(5.5)undecan-derivate und drogen, die dasselbe als aktiven inhaltsstoff enthalten
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
CN1264847C (zh) 2001-05-14 2006-07-19 弗·哈夫曼-拉罗切有限公司 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途
MXPA04006280A (es) 2001-12-28 2004-09-27 Acadia Pharm Inc Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
KR100863854B1 (ko) * 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제
CN101410414A (zh) * 2006-01-30 2009-04-15 弗·哈夫曼-拉罗切有限公司 用于治疗hiv的具有协同作用的组合物

Also Published As

Publication number Publication date
IL200661A0 (en) 2010-05-17
WO2008119663A1 (en) 2008-10-09
TW200902020A (en) 2009-01-16
JP2010522707A (ja) 2010-07-08
US7625891B2 (en) 2009-12-01
CA2682639A1 (en) 2008-10-09
CN101646679A (zh) 2010-02-10
AU2008233930A1 (en) 2008-10-09
BRPI0809646A2 (pt) 2014-09-23
KR20090127298A (ko) 2009-12-10
EP2142555A1 (en) 2010-01-13
PE20090183A1 (es) 2009-03-12
MX2009010503A (es) 2009-10-19
CL2008000863A1 (es) 2008-11-07
US20080249087A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
AR065854A1 (es) Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros.
CU23926B1 (es) Derivado de oxopirazina y herbicida
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
MX2014000359A (es) Metodos plaguicidas que utilizan compuestos de 3 - piridin tiazol sustituido y derivados para combatir las plagas de animales ii.
AR086474A1 (es) Compuestos de pirazol pesticidas
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
AR057350A1 (es) Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas
AR077505A1 (es) Compuestos de piridina y sus usos
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
CO6290685A2 (es) Compuestos de carbamoilo como inhibidores de la dgat1 190
ECSP14020586A (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
AR061644A1 (es) Derivados de benzofurano
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
AR067271A1 (es) Derivados de triazolona inhibidores no nucleosidos de la transcriptasa inversa, utiles para el tratamiento de enfermedades mediadas por el vih o el arc y composiciones farmaceuticas que los contienen.
AR059040A1 (es) Cis-4, 5- biaril-2- heterociclico imidazolinas como inhibidores de la mdm 2
AR077818A1 (es) Composiciones pesticidas
GB201201744D0 (en) Novel compounds
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
BR112014008196B8 (pt) processo para a preparação de um composto da fórmula (i)
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure